The effect of entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its relationship to HBeAg sero-conversion.
- Author:
Jian-xiang LI
1
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Antiviral Agents; therapeutic use; Cell Proliferation; drug effects; DNA, Viral; blood; genetics; Female; Guanine; analogs & derivatives; therapeutic use; Hepatitis B e Antigens; blood; Hepatitis B virus; drug effects; genetics; immunology; Hepatitis B, Chronic; blood; drug therapy; virology; Humans; Interferon-alpha; blood; Male; T-Lymphocytes; cytology; drug effects; Time Factors; Transaminases; blood; Treatment Outcome
- From: Chinese Journal of Experimental and Clinical Virology 2008;22(2):122-123
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the effect of Entecavir treatment on HBV-specific immunity in patient with chronic hepatitis B and its relationship to HBeAg sero-conversion.
METHODSSerum aminotransferase (ALT), HBV DNA and HBeAg were monitored before the after entecavir treatment. At the same time point, HBV-specific T cell proliferation was determined by [3H] T-dR incorporation assay, while HBV-specific IFN-alpha secretion was measured by ELISA.
RESULTSThe level of HBV DNA and ALT was significantly decreased after entecavir treatment. Same is the titer of HBeAg. In addition, HBeAg sero-conversion was observed in some of them, in whom the HBV-specific T cell proliferation and IFN-alpha production were significantly increased.
CONCLUSIONEntecavir treatment resulted in increased HBV-specific immunity along with the inhibition of HBV replication.
